These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 25960653)
1. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier. Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653 [TBL] [Abstract][Full Text] [Related]
2. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646 [TBL] [Abstract][Full Text] [Related]
3. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Zou S; Cao N; Cheng D; Zheng R; Wang J; Zhu K; Shuai X Int J Nanomedicine; 2012; 7():3823-35. PubMed ID: 22888237 [TBL] [Abstract][Full Text] [Related]
4. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
5. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer. Xu C; Wang P; Zhang J; Tian H; Park K; Chen X Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261 [TBL] [Abstract][Full Text] [Related]
7. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas. Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518 [TBL] [Abstract][Full Text] [Related]
8. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892 [TBL] [Abstract][Full Text] [Related]
9. Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy. Jin W; Wang Q; Wu M; Li Y; Tang G; Ping Y; Chu PK Biomaterials; 2017 Jun; 129():83-97. PubMed ID: 28329693 [TBL] [Abstract][Full Text] [Related]
10. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance. Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118 [TBL] [Abstract][Full Text] [Related]
11. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Ma X; Zhao Y; Ng KW; Zhao Y Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533 [TBL] [Abstract][Full Text] [Related]
12. Stimulus-responsive drug/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy. Mousazadeh H; Bonabi E; Zarghami N Carbohydr Polym; 2022 Jan; 276():118747. PubMed ID: 34823779 [TBL] [Abstract][Full Text] [Related]
13. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy. Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581 [TBL] [Abstract][Full Text] [Related]
14. Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. Mizusako H; Tagami T; Hattori K; Ozeki T J Pharm Sci; 2015 Sep; 104(9):2934-40. PubMed ID: 25940848 [TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307 [TBL] [Abstract][Full Text] [Related]
16. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related]
17. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR. Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258 [TBL] [Abstract][Full Text] [Related]
18. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer. Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors. Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479 [TBL] [Abstract][Full Text] [Related]
20. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]